Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 3, 2009, Pages 485-493

  Vilahur, G ^a,b   Hernandez Vera R ^a,b   Molins, B ^a,b   Casani L ^a,b   Duran, X ^a   Padro T ^a   Badimon, Lina ^a,b,c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Inflammation; Ischemia; mCRP; Mononuclear cells; Myocardial infarction; Platelets

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2; CYTOKINE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON OCCLUSION; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE INFARCTION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTIC INFILTRATION; MOLECULAR BIOLOGY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHAM PROCEDURE; SWINE; THROMBOCYTE ACTIVATION; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CYCLOOXYGENASE 2; CYTOKINES; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; INFLAMMATION; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; SWINE; THROMBOPLASTIN; UP-REGULATION;

EID: 59849116052     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03244.x     Document Type: Article

References (30)

1. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiol 2001; 38: 478-85.
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-20.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
4. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39: 1917-23.
5. Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis 2004; 172: 1-6.
6. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 1995; 92: 1866-75.
7. Kakio T, Matsumori A, Ono K, Ito H, Matsushima K, Sasayama S. Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart. Lab Invest 2000; 80: 1127-36.
8. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: Theory versus practice. Circulation 1999; 100: 1148-50.
9. Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, Fuster V, Sanz J, Badimon JJ. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 2007; 115: 2909-16.
10. Lawrence MB, McIntire LV, Eskin SG. Effect of flow on polymorphonuclear leukocyte/endothelial cell adhesion. Blood 1987; 70: 1284-90.
11. Bulhak A, Roy J, Hedin U, Sjoquist PO, Pernow J. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Am J Physiol Heart Circ Physiol 2007; 292: H3158-63.
12. Tam CS, Wong M, Tam K, Aouad L, Waters KA. The effect of acute intermittent hypercapnic hypoxia treatment on IL-6, TNF-alpha, and CRP levels in piglets. Sleep 2007; 30: 723-7.
13. Martinez-Subiela S, Eckersall PD, Campbell FM, Parra MD, Fuentes P, Ceron JJ. A time-resolved immunofluorometric assay for porcine C-reactive protein quantification in whole blood. Luminescence 2007; 22: 171-6.
14. Wu Y, Wang HW, Ji SR, Sui SF. Two-dimensional crystallization of rabbit C-reactive protein monomeric subunits. Acta Crystallogr D Biol Crystallogr 2003; 59: 922-6.
15. Diehl EE, Haines GK 3rd, Radosevich JA, Potempa LA. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 2000; 319: 79-83.
16. Krupinski J, Turu MM, Martinez-Gonzalez J, Carvajal A, Juan-Babot JO, Iborra E, Slevin M, Rubio F, Badimon L. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke 2006; 37: 1200-4.
17. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-46.
18. Khreiss T, Jozsef L, Potempa LA, Filep JG. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004; 110: 2713-20.
19. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 2004; 109: 2016-22.
20. Potempa LA, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H. Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 1988; 12: 391-405.
21. Turu MM, Slevin M, Matou S, West D, Rodriguez C, Luque A, Grau-Olivares M, Badimon L, Martinez-Gonzalez J, Krupinski J. C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biol 2008; 9: 47.
22. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993; 91: 1351-7.
23. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: Special reference to monocyte chemoattractant protein-1. Hypertension 2003; 41: 834-41.
24. Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004; 4: 116-23.
25. Badimon L, Badimon JJ, Vilahur G, Segales E, Llorente V. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 2002; 32: 225-31.
26. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70: 389-99.
27. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
28. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
29. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-54.
30. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007; 100: 1659-64.